The clinical development process for a novel preventive vaccine
Open Access
- 1 January 2016
- journal article
- review article
- Published by Medknow in Journal of Postgraduate Medicine
- Vol. 62 (1), 4-11
- https://doi.org/10.4103/0022-3859.173187
Abstract
Each novel vaccine candidate needs to be evaluated for safety, immunogenicity, and protective efficacy in humans before it is licensed for use. After initial safety evaluation in healthy adults, each vaccine candidate follows a unique development path. This article on clinical development gives an overview on the development path based on the expectations of various guidelines issued by the World Health Organization (WHO), the European Medicines Agency (EMA), and the United States Food and Drug Administration (USFDA). The manuscript describes the objectives, study populations, study designs, study site, and outcome(s) of each phase (Phase I-III) of a clinical trial. Examples from the clinical development of a malaria vaccine candidate, a rotavirus vaccine, and two vaccines approved for human papillomavirus (HPV) have also been discussed. The article also tabulates relevant guidelines, which can be referred to while drafting the development path of a novel vaccine candidate.Keywords
This publication has 36 references indexed in Scilit:
- Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 yearsHuman Vaccines & Immunotherapeutics, 2012
- Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in AfricaMalaria Journal, 2011
- Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccinesVaccine, 2010
- Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of ageVaccine, 2009
- Rotavirus Vaccine RIX4414 (Rotarix™)Pediatric Drugs, 2009
- Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02PLOS ONE, 2008
- An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial resultsVaccine, 2008
- Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III studyThe Lancet, 2008
- Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV InfectionThe Journal of Infectious Diseases, 2007
- Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trialsCMAJ : Canadian Medical Association Journal, 2007